{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:22:34Z","timestamp":1771867354894,"version":"3.50.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1097\/inf.0b013e3181fcb2bf","type":"journal-article","created":{"date-parts":[[2010,10,14]],"date-time":"2010-10-14T10:26:45Z","timestamp":1287052005000},"page":"190-196","source":"Crossref","is-referenced-by-count":25,"title":["Immunogenicity and Safety of an Investigational Combined Haemophilus influenzae Type B-Neisseria meningitidis Serogroups C and Y-Tetanus Toxoid Conjugate Vaccine"],"prefix":"10.1097","volume":"30","author":[{"given":"Terry","family":"Nolan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jodie","family":"McVernon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karyn","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narcisa","family":"Mesaros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Aris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Poolman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Boutriau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210202","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease.","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"key":"R2-3-20210202","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1574-6976.2006.00060.x","article-title":"A surveillance network for meningococcal disease in Europe.","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"R4-3-20210202","first-page":"1","article-title":"Prevention and control of meningococcal disease.","volume":"54","author":"Bilukha","year":"2005","journal-title":"MMWR"},{"key":"R5-3-20210202","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease.","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R7-3-20210202","first-page":"1","article-title":"Annual report of the Australian Meningococcal Surveillance Programme, 2007\u2014Amended.","volume":"33","author":"Tapsall","year":"2009","journal-title":"Commun Dis Intell"},{"key":"R8-3-20210202","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/erv.10.3","article-title":"The epidemiology of meningococcal disease and the impact of vaccines.","volume":"9","author":"Khatami","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"R9-3-20210202","first-page":"196","article-title":"Annual report of the Australian Meningococcal Surveillance Programme, 2002.","volume":"27","year":"2003","journal-title":"Commun Dis Intell"},{"key":"R10-3-20210202","first-page":"407","article-title":"Annual report of the Australian Meningococcal Surveillance Programme, 2001.","volume":"26","year":"2002","journal-title":"Commun Dis Intell"},{"key":"R11-3-20210202","first-page":"113","article-title":"Annual report of the Australian Meningococcal Surveillance Programme, 2000.","volume":"25","year":"2001","journal-title":"Commun Dis Intell"},{"key":"R12-3-20210202","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.inf.0000195594.41449.c6","article-title":"Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands.","volume":"25","author":"de Greeff","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"R13-3-20210202","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1086\/315158","article-title":"The changing epidemiology of meningococcal disease in the United States 1992\u20131996.","volume":"180","author":"Rosenstein","year":"1999","journal-title":"J Infect Dis"},{"key":"R15-3-20210202","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.vaccine.2005.03.045","article-title":"Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.","volume":"23","author":"Larrauri","year":"2005","journal-title":"Vaccine"},{"key":"R16-3-20210202","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5694\/j.1326-5377.2007.tb00828.x","article-title":"Impact of meningococcal C conjugate vaccine use in Australia.","volume":"186","author":"Booy","year":"2007","journal-title":"Med J Aust"},{"key":"R18-3-20210202","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"key":"R19-3-20210202","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1016\/j.vaccine.2007.10.013","article-title":"A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants.","volume":"25","author":"Nolan","year":"2007","journal-title":"Vaccine"},{"key":"R20-3-20210202","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/INF.0b013e3181c3ce88","article-title":"Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.","volume":"29","author":"Marchant","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R21-3-20210202","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays.","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"R24-3-20210202","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from post-licensure surveillance in England.","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"R25-3-20210202","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R26-3-20210202","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/infdis\/149.6.1034","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.","volume":"149","author":"Anderson","year":"1984","journal-title":"J Infect Dis"},{"key":"R27-3-20210202","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/147.6.1100","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.","volume":"147","author":"K\u00e4yhty","year":"1983","journal-title":"J Infect Dis"},{"key":"R28-3-20210202","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1586\/erv.09.32","article-title":"Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV\/Hib hexavalent vaccine).","volume":"8","author":"Zepp","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"R30-3-20210202","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/INF.0b013e3181cdd379","article-title":"Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups c and y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age.","volume":"29","author":"Marshall","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R31-3-20210202","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"R32-3-20210202","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/adc.88.5.379","article-title":"Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure.","volume":"88","author":"McVernon","year":"2003","journal-title":"Arch Dis Child"},{"key":"R33-3-20210202","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/adc.2007.136036","article-title":"A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.","volume":"93","author":"Pace","year":"2008","journal-title":"Arch Dis Child"},{"key":"R34-3-20210202","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/CVI.00384-09","article-title":"Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine.","volume":"17","author":"Borrow","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R35-3-20210202","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/INF.0b013e3181b9a831","article-title":"A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months.","volume":"29","author":"D\u00edez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R36-3-20210202","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0264-410X(96)00086-2","article-title":"Study of booster doses of two Haemophilus influenzae type b conjugate vaccines including their interchangeability.","volume":"14","author":"Scheifele","year":"1996","journal-title":"Vaccine"},{"key":"R37-3-20210202","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1016\/j.vaccine.2009.03.064","article-title":"Antigen processing of glycoconjugate vaccines; the polysaccharide portion of the pneumococcal CRM(197) conjugate vaccine co-localizes with MHC II on the antigen processing cell surface.","volume":"27","author":"Lai","year":"2009","journal-title":"Vaccine"},{"key":"R38-3-20210202","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/clinids\/7.4.504","article-title":"Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes.","volume":"7","author":"Frasch","year":"1985","journal-title":"Rev Infect Dis"},{"key":"R39-3-20210202","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.vaccine.2003.09.009","article-title":"Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation.","volume":"22","author":"Bonhoeffer","year":"2004","journal-title":"Vaccine"},{"key":"R40-3-20210202","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CVI.00420-08","article-title":"Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with a 7-valent pneumococcal conjugate vaccine and a combination DTaP5\/Hib\/IPV vaccine in healthy UK infants.","volume":"16","author":"Southern","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"R41-3-20210202","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(99)04377-9","article-title":"Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis.","volume":"354","author":"Eskola","year":"1999","journal-title":"Lancet"},{"key":"R42-3-20210202","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.ijid.2009.03.004","article-title":"Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic.","volume":"14","author":"Marshall","year":"2010","journal-title":"Int J Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006454-201103000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T05:58:37Z","timestamp":1618034317000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201103000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e3181fcb2bf","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}